Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 22, 2017
Pharmacy Choice - Pharmaceutical News - Analyst Upgrades Achillion Pharmaceuticals (NASDAQ:ACHN) Stock Gets Upgraded By Leerink Swann from Market Perform to Outperform - July 22, 2017

Pharmacy News Article

 5/19/17 - Analyst Upgrades Achillion Pharmaceuticals (NASDAQ:ACHN) Stock Gets Upgraded By Leerink Swann from Market Perform to Outperform

Analyst Ratings For Achillion Pharmaceuticals (NASDAQ:ACHN)

Today, Achillion Pharmaceuticals (NASDAQ:ACHN) stock received an upgrade by Leerink Swann from Market Perform to Outperform.

There are 2 hold ratings, 7 buy ratings on the stock.

The current consensus rating on Achillion Pharmaceuticals (NASDAQ:ACHN) is Buy (Score: 2.78) with a consensus target price of $10.13 per share, a potential 129.59% upside.

Some recent analyst ratings include

  • 5/18/2017-Leerink Swann Upgrade from a Market Perform rating to a Outperform rating.
  • 4/26/2017-Jefferies Group LLC Reiterated Rating of Hold.
  • 2/2/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
  • 11/4/2016-Chardan Capital Upgrade from a Sell rating to a Neutral rating.
  • 11/3/2016-Wedbush Reiterated Rating of Outperform.

Dividend information for Achillion Pharmaceuticals (NASDAQ:ACHN)

.
Recent Insider Trading Activity For Achillion Pharmaceuticals (NASDAQ:ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) has insider ownership of 6.52% and institutional ownership of 77.85%.

  • On 12/22/2016 Jason S Fisherman, Director, bought 10,000 with an average share price of $3.96 per share and the total transaction amounting to $39,600.00. View SEC Filing
  • On 12/5/2016 Mary Kay Fenton, CFO, bought 2,500 with an average share price of $4.11 per share and the total transaction amounting to $10,275.00. View SEC Filing
  • On 12/2/2016 Joel C Barrish, Insider, bought 2,500 with an average share price of $4.06 per share and the total transaction amounting to $10,150.00. View SEC Filing
  • On 12/30/2015 David Apelian, insider, sold 10,000 with an average share price of $10.50 per share and the total transaction amounting to $105,000.00. View SEC Filing
  • On 12/28/2015 Mary Kay Fenton, CFO, sold 43,500 with an average share price of $10.08 per share and the total transaction amounting to $438,480.00. View SEC Filing
  • On 11/11/2015 Nicole Vitullo, Director, sold 550,000 with an average share price of $10.17 per share and the total transaction amounting to $5,593,500.00. View SEC Filing
  • On 9/25/2015 Nicole Vitullo, Director, sold 9,310 with an average share price of $8.22 per share and the total transaction amounting to $76,528.20. View SEC Filing

About Achillion Pharmaceuticals (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Recent Trading Activity for Achillion Pharmaceuticals (NASDAQ:ACHN)
Shares of Achillion Pharmaceuticals closed the previous trading session at 4.41 up +0.63 16.67% with 5,742,277 shares trading hands.

The post Analyst Upgrades Achillion Pharmaceuticals (NASDAQ:ACHN) Stock Gets Upgraded By Leerink Swann from Market Perform to Outperform appeared first on Market Exclusive.



© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jul 23: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Jul 24: What's New? New Treatments for Type 2 Diabetes
Jul 26: Management of Schizophrenia & Acute Agitation
Jul 27: On the Move: A Comprehensive Review of Osteoarthritis, Gout & Rheumatoid Arthritis
Jul 31: Obesity Management: Overview of Pharmacotherapy
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415